David Chang

Chief Executive Officer
Taiwan Bio-Manufacturing Corporation  (TBMC)
​
​​

Dr. David Chang has 30-year industrial experience, and is currently the CEO of TBMC (Taiwan Bio-Manufacturing Co), Taiwan.  Prior to current role, he was CEO of Wuxi AppTec Advanced Therapies Business Unit located in Philadelphia, PA.; Corporate VP and Head of Cell Therapy Global Manufacturing, of Celgene Corporation; the Global Head of Engineering and Strategy at Roche based in Basel, Switzerland; the VP/Site Head of Roche Shanghai Technical Operations in China.  Earlier in his career, Dr. David Chang worked at Genentech as the Senior Director of Global Manufacturing Science and Technology, and as the Director of Process Development in its Oceanside, CA site.  He was also formerly at Biogen Idec as Director of cell culture R&D, at BASF Bioresearch as a cell culture group leader, and at Schering-Plough Research Institute as a process development engineer.  Dr. David Chang obtained his Bachelor’s degree in Chemical Engineering from National Taiwan University in Taiwan, and the Master’s and PhD degrees in Biochemical Engineering​ from MIT in Massachusetts, USA.
 

Speech title & Synopsis

Integration of MSC Value Chain with Enabling Manufacturing Platforms

Mesenchymal stromal cells (MSCs) are clinically important adult stem cells capable of modulating immune system, influencing microenvironment around damaged tissues and enhancing tissue repair, thus offering a broad perspective in cell-based therapies for neurological, musculoskeletal diseases and most recent Coronavirus infectious disease.  In order to provide right quality and cost effective MSCs for clinical applications, TBMC has embarked on the development of proprietary cell lines, serum-free culture media, delivery hydrogel and fully automated and qualified cell processing platforms.  These platforms are readily available to support MSC clinical development and commercial supplies globally.